Human Anti-EBOV GP Recombinant Antibody (clone ma-B06)
CAT#: FAMAB-0526WJ
This product is a human monoclonal antibody reacted with EBOV GP. This antibody can be used in a variety of applications, such as ELISA, WB, Neut, IP.
Published Data
Neut
Figure 1 Neutralization of vaccination-induced macaque monoclonal antibodies (mAbs).
Bar chart representing the values of half-maximal inhibitory concentration ([IC50] μg/mL) calculated after in vitro neutralization assay using Zaire ebolavirus (EBOV) glycoprotein (GP)-pseudotyped-virus performed with the 14 mAbs that were cloned. In gray are negative controls VRC01 and mAb114 used as a reference. Seven of 14 mAbs showed ability to neutralize in vitro.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
Neut
Figure 2 Neutralization of vaccination-induced macaque monoclonal antibodies (mAbs).
Dot plots show the-log half-maximal effective concentration ([EC50] μg/mL) representing binding of the 7 neutralizers identified in A to GP (filled circles) and GPΔMUC (empty circles). All of the mAbs tested bound GPΔMUC with greater potency compared with GP (P = .0097).
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
IP
Figure 3 Immunoprecipitation of the 7 neutralizers performed with GPTHL.
Four of seven mAbs were able to precipitate GPTHL. As control, input GPTHL is shown on a Coomassie-stained gel.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
WB
Figure 4 Western blot on the 4 mAbs identified in C performed with GPΔMUC and GPTHL.
For mAb114, none of the mAbs tested were able to bind GPTHL by Western blot. As a positive control for GPTHL, binding of polyclonal serum is shown.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
Inhib
Figure 5 Bar chart representing the percentage of binding inhibition of biotinylated mAb114 to GPΔMUC in the presence of each of the 4 putative mAb114-like antibodies.
All mAbs showed a high degree of competition with mAb114 for binding to GPΔMUC (calculated at the concentration of 8 μg/mL). The gray bar shows the maximal degree of self-competition of mAb114.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
Figure 6 Bar chart on the binding kinetics of the GP1 core antibodies compared with mAb114.
log (KD) values were calculated by biolayer interferometry performed with Fab binding to GPΔMUC at neutral and low pH (black and dark gray bars, respectively) as well as to GPTHL at low pH only (light gray bars). All monoclonal antibodies (mAbs) showed similar kinetics compared with mAb114 with ma-D08 showing slightly lower values. Fab fragments derived from papain digestion of mAbs were used for measuring kinetics. This experiment was performed twice. Values are shown from 1 representative experiment.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
Figure 7 Bar chart on competition of the GP1 core antibodies with NPC1-dC compared with mAb114 performed by biolayer interferometry using whole IgG binding to GPTHL.
All mAbs showed similar competition with NPC1-dC for binding to GPTHL. Human immunodeficiency virus GP120 (indicated as "Control") and 2 additional mAbs (KZ52 and mAb100) that are known to bind the base of GPTHL far from the receptor binding domain (RBD) were used as negative controls. NPC1-dC was used to assess the maximal degree of self-competition. This experiment was also performed twice, and values are shown from 1 representative experiment.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
Figure 8 Electron microscopy reveals that all of the RBD blockers approach glycoprotein (GP) vertically but with a slightly more open angle compared with mAb114 (Fab indicated with green stars).
The scale bars are 10 nm.
Cagigi, A., Misasi, J., Ploquin, A., Stanley, D. A., Ambrozak, D., Tsybovsky, Y., ... & Sullivan, N. J. (2018). Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures. The Journal of Infectious Diseases, 218(suppl_5), S528-S536.
❮
❯
Specifications
- Host Species
- Human
- Type
- Human IgG
- Specificity
- EBOV GP
- Species Reactivity
- EBOV
- Clone
- ma-B06
- Applications
- ELISA, WB, Neut, IP
- Related Disease
- EBOV infection
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for FAMAB-0526WJ. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "EBOV GP"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-298-S(P) | Recombinant Anti-EBOV GP Antibody scFv Fragment | IF, FC, Biosensors, FuncS | scFv |
| MHH-298-S(P) | Recombinant Human Anti-EBOV GP Antibody scFv Fragment | WB, IF, FuncS | scFv |
| PSBW-038 | Recombinant Mouse Anti-EBOV GP Antibody scFv Fragment (14G7) | ELISA, Neut | scFv |
| HPAB-1098WJ-S(P) | Mouse Anti-EBOV GP Recombinant Antibody; scFv Fragment (HPAB-1098WJ-S(P)) | ELISA, WB | Mouse scFv |
| PABJ-0059-S(P) | Human Anti-EBOV GP Recombinant Antibody (clone 1T0227); scFv Fragment | ELISA | Human scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MHH-298 | Recombinant Human Anti-EBOV GP Antibody | IF, FC, Biosensors, FuncS | IgG |
| HPAB-N0106-YC | Macaque Anti-EBOV GP Recombinant Antibody (HPAB-N0106-YC) | ELISA, FC, Neut | Macaque IgG |
| HPAB-1098WJ | Mouse Anti-EBOV GP Recombinant Antibody (HPAB-1098WJ) | ELISA, WB | Mouse IgG, κ |
| HPAB-0734YY | Human Anti-EBOV GP Recombinant Antibody (HPAB-0734YY) | ELISA, Neut | Human IgG1 |
| HPAB-0735YY | Human Anti-EBOV GP Recombinant Antibody (HPAB-0735YY) | ELISA, Neut | Humanized IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBL-455 | Recombinant Human Anti-EBOV GP Antibody Fab Fragment (KZ52 ) | Neut | Fab |
| PFBC-260 | Recombinant Human Anti-EBOV GP Antibody Fab Fragment (c2G4) | ELISA, Neut | Human Fab |
| PFBC-261 | Recombinant Human Anti-EBOV GP Antibody Fab Fragment (c13C6) | ELISA, Neut | Human Fab |
| PFBC-262 | Recombinant Human Anti-EBOV GP Antibody Fab Fragment (c4G7) | ELISA, Neut, WB | Human Fab |
| HPAB-0411-FY-F(E) | Human Anti-EBOV GP Recombinant Antibody; Fab Fragment (HPAB-0411-FY-F(E)) | ELISA, Neut | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-916LC | Mouse Anti-EBOV GP Recombinant Antibody (MRO-916LC) | ELISA | Mouse IgG, κ |
| MRO-937LC | Anti-EBOV GP Recombinant Antibody (CAN9G1) | ELISA, WB | Mouse antibody |
| MRO-938LC | Anti-EBOV GP Recombinant Antibody (CAN8G1) | ELISA, WB | Mouse antibody |
| MRO-939LC | Anti-EBOV GP Recombinant Antibody (CAN7G1) | ELISA, WB | Mouse antibody |
| MRO-900LC-F(E) | Anti-EBOV GP Recombinant Antibody Fab Fragment (13F6) | ELISA | Mouse antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-917LC | Anti-EBOV GP Recombinant Antibody (EVB100) | ELISA | Human antibody |
| MRO-918LC | Anti-EBOV GP Recombinant Antibody (EVB166) | ELISA | Human antibody |
| MRO-919LC | Anti-EBOV GP Recombinant Antibody (EVB167) | ELISA | Human antibody |
| MRO-920LC | Anti-EBOV GP Recombinant Antibody (EVB165) | ELISA | Human antibody |
| MRO-921LC | Anti-EBOV GP Recombinant Antibody (EVB114v1) | ELISA | Human antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-927LC | Mouse Anti-EBOV GP Recombinant Antibody (MRO-927LC) | ELISA | Mouse IgG1, κ |
| MRO-927LC-S(P) | Mouse Anti-EBOV GP Recombinant Antibody (MRO-927LC-S(P)); scFv Fragment | ELISA | Mouse scFv |
| MRO-927LC-F(E) | Mouse Anti-EBOV GP Recombinant Antibody (MRO-927LC-F(E)); Fab Fragment | ELISA | Mouse Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| EPAF-0983LC | Recombinant Mouse Anti-EBOV GP Antibody (133/3.16) | ELISA, FuncS | IgG1 |
| EPAF-0213CQ | Recombinant Mouse Anti-EBOV GP Antibody (226/8.1) | Neut | IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0625-XY9 | Human Anti-EBOV GP Vaccinal Antibody (VS-0625-XY9) | ELISA, FC, Neut | Human IgG1 |
| VS-0625-XY10 | Monkey Anti-EBOV GP Vaccinal Antibody (VS-0625-XY10) | ELISA, BLI, Neut | Monkey IgG |
| VS-0625-XY11 | Human Anti-EBOV GP Vaccinal Antibody (VS-0625-XY11) | ELISA, BLI, FC, Neut | Human IgG1 |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: WB, IHC, FC, Cyt, ELISA
Application: Neut, ELISA, FuncS
Application: WB, ELISA, FuncS, Inhib, PK, IP, SPR
-3.jpg)
Application: Neut
Application: ELISA, FC, IHC, Neut
Application: FC, IA, IF, IP, IHC, FuncS
Application: ELISA, Inhib, FC, Neut
Application: ELISA, FC
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
